H+ is a pioneering research project in the fields of neural interfaces, augmented reality, biohacking, bionic prosthetics, genetic engineering, nanorobotics, tissue engineering, and wearable technology. Founded in 2017, H+ focuses on cutting-edge advancements in AI and VR/AR technologies, with a primary emphasis on revolutionizing the integration of technology with the human body.
With its comprehensive scope that spans multiple industries, H+ is at the forefront of innovation, exploring the convergence of various disciplines to push the boundaries of what is possible in the realm of human augmentation. Its ambitious pursuit of breakthroughs in neural interfaces, genetic engineering, and wearable technologies positions H+ as a key player in defining the future of human-machine interaction.
While headquartered information is not available, H+ represents a compelling investment opportunity for venture capital firms seeking to engage with startups at the vanguard of technological and biological integration. As H+ continues to push the envelope in its research and developments, it presents the potential for substantial impact and disruptive advancements within the tech landscape.
For investors looking to support ventures that are at the intersection of cutting-edge technologies and human enhancement, H+ offers an exciting prospect for participation in the shaping of the future. Given the diverse range of fields that H+ operates in, from genetic engineering to wearable tech, the potential for innovative breakthroughs and substantial market impact is significant.
There is no investment information